Selected Articles from This Issue

Highlights| March 01 2024 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2024 American Association for Cancer Research2024American Association for Cancer Research Clin Cancer Res (2024) 30 (5): 929. https://doi.org/10.1158/1078-0432.CCR-30-5-HI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record March 1 2024 Citation Selected Articles from This Issue. Clin Cancer Res 1 March 2024; 30 (5): 929. https://doi.org/10.1158/1078-0432.CCR-30-5-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Addition of anti-PD-1 and PD-L1 immunotherapies to chemotherapy and radiation for the treatment of cervical cancer has had mixed clinical results. As TGF-β has been shown to promote tumor progression and immune escape in human papillomavirus (HPV)-associated cervical cancer, it has been suggested that targeting both the immunosuppressive TGF-β and PD-L1 pathways may improve patient outcomes. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of a TGF-β "trap" fused to a PD-L1 monoclonal antibody. In this phase Ib trial, Oaknin and colleagues evaluate the combination of bintrafusp alfa with cisplatin or carboplatin plus paclitaxel or radiation, with or without the VEGF-A monoclonal antibody bevacizumab in patients with locally advanced or persistent, recurrent, or metastatic (P/R/M) cervical cancer. The combination therapies were tolerable, with most adverse events being grade 1-2. The authors report promising activity, with an objective response rate of 75.0% in patients receiving bintrafusp alfa, cisplatin or carboplatin,... You do not currently have access to this content.